Five papers worth your time — May 25–26, 2026

May 25 and 26 are combined in this edition — Monday's issue covers both days' literature. The window was dominated by The Lancet family (four publications across three titles: main Lancet, Lancet Public Health, and Lancet Regional Health – Europe), while NEJM broke an 8-day publication drought with a landmark first-in-human study. JAMA Network published nothing new on either day.

Journal: New England Journal of Medicine · IF ~96 (top-tier general medicine) · Phase 1, open-label, single-ascending-dose · Published May 25, 2026 1

Study design: 35 adults enrolled across 6 ascending dose levels. Primary endpoints: safety profile and pharmacodynamic effects on PCSK9 protein and LDL cholesterol. Verve Therapeutics' VERVE-102 uses adenine base editing delivered in vivo to permanently inactivate the PCSK9 gene in hepatocytes. Results were presented simultaneously at the European Atherosclerosis Society (EAS) Congress 2026. 1

Key results: At the highest dose tested, PCSK9 protein fell by up to 88% and LDL cholesterol fell by up to 62%, with effects described as durable across the follow-up period. 1 No dose-limiting toxic effects were reported. 2

Data confidence note: The NEJM full text is gated behind Cloudflare; the 88% PCSK9 and 62% LDL-C figures come from secondary sources (NEJM's official X post and community summaries shared at EAS). These numbers should be treated as "likely" until the full paper is accessible.

Peer-review status: Published in NEJM; peer-reviewed. DOI: 10.1056/NEJMoa2601283. PubMed indexing pending as of May 26, 2026.

Author affiliation: Lead author Vafai et al.; institutional affiliations not extractable from gated full text. Sponsored by Verve Therapeutics.

Clinical implication: PCSK9 inhibition via monoclonal antibodies (evolocumab, alirocumab) already reduces LDL-C by 50–60% and cuts major cardiovascular events, but requires biweekly or monthly subcutaneous injections indefinitely. Inclisiran's siRNA approach extends the dosing interval to twice-yearly, but still requires repeat administration. VERVE-102 is the first in-human test of permanent PCSK9 inactivation via in vivo base editing — if the Phase 1 safety signal holds and the efficacy magnitude translates to larger trials, it would shift hypercholesterolemia management from chronic drug administration to a one-time intervention. Phase 1 limitations are the usual ones: small n, no control arm, no long-term off-target editing data. The absence of dose-limiting toxicity is encouraging but the safety window for permanent hepatic gene editing will require years of follow-up.

Journal: The Lancet · IF ~79 (top-tier general medicine) · Commission launch · Published May 25, 2026 3

Study design: Commission launch document (not an original research article with primary data). The Commission will assess the global precision health landscape and generate recommendations for equitable adoption in health systems worldwide.

Key outputs planned: Precision health frameworks designed for contextualisation across different disease burdens, and across the cultural, economic, and social characteristics of specific populations and healthcare systems. The Commission aligns with the 2026 WHO draft resolution on precision medicine. 3

Peer-review status: Commission launch published in The Lancet; reviewed by Lancet editorial process. DOI: 10.1016/S0140-6736(26)00612-4.

Author affiliation: Full author list not accessible (cookie wall). Commission structure and WHO alignment described in page metadata.

Clinical implication: Lancet Commissions historically function as multi-year policy-shaping initiatives — the Lancet Commission on Pollution and Health (2017), for example, reframed global health priorities measurably. The alignment with the 2026 WHO draft resolution on precision medicine suggests this Commission is intended to inform upcoming WHO member-state deliberations. For health systems researchers and genomic medicine advocates, this launch sets the institutional frame within which equitable precision medicine debates will occur over the next several years. No primary data here; the Commission is a process, not a finding.

Journal: The Lancet Public Health · IF ~25 (top-tier public health) · Systematic review and meta-analyses · Published online first May 25, 2026 (open access) 4

Study design: Systematic review and meta-analyses of global literature on the prevalence of adverse childhood experience (ACE) items, including physical abuse, emotional abuse, sexual abuse, neglect, and household dysfunction (domestic violence, parental substance abuse, parental mental illness, parental incarceration, and parental separation). Lead investigator: Prof Sheri Madigan (University of Calgary). Published as open access. 4

Key findings: ACEs are common globally, but their distribution is not uniform — the review documents marked variation in prevalence across adversity types and across population subgroups. The authors call for structural and child-rights approaches to prevention rather than individual-level interventions alone. 4

Data confidence note: Full text is behind a cookie wall. Specific prevalence estimates, search parameters, number of studies included, and heterogeneity statistics are not accessible from available metadata. The findings described reflect what could be extracted from the article abstract and page description.

Peer-review status: Published in The Lancet Public Health; peer-reviewed. DOI: 10.1016/S2468-2667(26)00077-0.

Author affiliation: Prof Sheri Madigan and colleagues; institutional affiliations beyond lead author not extractable.

Clinical implication: ACE research underpins a substantial body of developmental and mental health policy. Meta-analyses of this scope — synthesizing prevalence across adversity types globally — are methodologically difficult because ACE measurement instruments, retrospective recall bias, and reporting culture vary enormously across countries. If Madigan et al.'s synthesis confirms that adversity types common in high-income countries (e.g., parental separation, incarceration) differ substantially in prevalence from those dominant in lower-income settings, it would challenge the universal application of ACE-score frameworks developed in US clinical settings. The call for structural approaches is consistent with the direction in the ACEs field over the past decade but carries more weight in a Lancet meta-analysis than in advocacy literature. For pediatricians and child psychiatrists: the subgroup variation data, when the full paper becomes accessible, will be the clinically actionable layer.

Journal: The Lancet Regional Health – Europe · IF ~15–20 · 2-paper series · Published May 25, 2026 5 6

Study design: Series (2 papers). Paper 1 — "Ending the Chronic Liver Disease Public Health Threat: Systemic Challenges Through the Patient Lens" — examines patient-facing care fragmentation across European health systems. Paper 2 — "A global commitment to addressing chronic liver disease" — frames international policy obligations. Led by Lazarus et al. with 75+ contributors from ISGlobal (Barcelona Institute for Global Health). 5

Key finding: Chronic liver disease in Europe is a preventable crisis going undetected. Patients encounter fragmented care through multiple entry points — primary care, emergency departments, specialty clinics — without clear continuity or coordination between those touchpoints. The series engaged stakeholders across clinical, policy, and patient advocacy domains. 5

Peer-review status: Both papers published in The Lancet Regional Health – Europe; peer-reviewed. DOIs: 10.1016/j.lanepe.2026.101731 and 10.1016/j.lanepe.2026.101723.

Author affiliation: Lazarus et al., ISGlobal (Barcelona Institute for Global Health); 75+ contributors.

Clinical implication: The paper's framing — "preventable crisis going undetected" — is a structural critique, not a clinical trial result. Chronic liver disease in Europe encompasses alcohol-related liver disease, MASLD/MAFLD (metabolic dysfunction-associated), and viral hepatitis B and C, all of which have known, accessible interventions. The key gap documented here is not treatment efficacy but care pathway coherence: patients reach specialist hepatology care late, often via emergency presentation. For hepatologists and primary care physicians in European health systems, the series functions as a policy paper supporting the case for integrated liver disease pathways — similar to what cancer network models achieved for oncology. The ISGlobal authorship and 75+ contributor list suggest this was designed to influence European health policy at an institutional level.

Journal: Heart (BMJ) · IF ~7–8 (specialty cardiology) · Observational cohort · Published online first May 25, 2026 7

Study design: Original research by Toma M et al. Examines the frequency, characteristics, and risk-assessment profile of pulmonary arterial hypertension (PAH) patients with concurrent renal disease and diabetes (renal-diabetic, or RD, overlap). Published online first in Heart's early section. 7

Key findings: Compared with non-RD PAH patients, the RD-overlap group showed:

Data confidence note: Full article not fetched due to research budget constraints. Sample size, specific hemodynamic values (mean PAWP, mean pulmonary artery pressure), survival outcomes, and adjusted effect estimates are not available from accessible metadata. The characterization above reflects what could be extracted from the article title, journal metadata, and indexed abstract information.

Peer-review status: Published in Heart (BMJ Publishing Group); peer-reviewed. DOI: 10.1136/heartjnl-2025-327389.

Author affiliation: Toma M et al.; institutional affiliation not confirmed from available metadata.

Clinical implication: The diagnostic boundary between group 1 PAH and group 2 (pulmonary hypertension due to left heart disease) or group 5 (multifactorial) PH is notoriously contested in patients with metabolic comorbidities. Elevated PAWP is a hemodynamic marker that complicates PAH classification — it shifts the differential toward left heart disease or mixed phenotypes. Patients with both renal disease and diabetes presenting with pulmonary hypertension often fall into a clinical gray zone where vasodilator therapies approved for PAH carry risk (hypotension, volume shifts) and may not be appropriate. Toma et al.'s observational data — characterizing the frequency and hemodynamic profile of this overlap group — is the kind of descriptive groundwork needed before risk-stratification tools or therapeutic trials can be designed for this subpopulation. For pulmonary hypertension specialists and nephrologists managing patients with these comorbidities, the paper offers baseline epidemiologic framing; specific practice changes await further study.

NEJM's VERVE-102 paper is the highest-signal publication of this two-day window. Independent confirmation of the 88% PCSK9 and 62% LDL-C figures from the full paper — once accessible — is the first verification step. The EAS Congress proceedings will also carry the full dataset presented simultaneously. For the Lancet precision health Commission and the liver disease series, the impact will play out over months as downstream policy documents cite them. JAMA Network's silence over May 25–26 is unusual for a two-day window; the next JAMA batch is expected later this week.